Management of older persons after myocardial infarction

Journal of the American Geriatrics Society

Volumn 46, Issue 11, 1998, Pages 1459-1468

  Aronow, Wilbert S ^a,b  

^a HEBREW HOSPITAL HOME   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CALCIUM CHANNEL AFFECTING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; ESTRADIOL; FLECAINIDE; GESTAGEN; ISOSORBIDE 2 NITRATE; MORACIZINE; PROPRANOLOL; QUINIDINE; SOTALOL; TIMOLOL; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; CARDIOVERSION; CLINICAL PROTOCOL; DIABETES MELLITUS; GERIATRIC CARE; HEART ARRHYTHMIA; HEART MUSCLE REVASCULARIZATION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; OBESITY; REVIEW; RISK FACTOR; TREATMENT PLANNING;

EID: 0031760387     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb06017.x     Document Type: Review

References (105)

1. Stenson WB, Sanders CA, Smith HC. Cardiovascular care of the elderly: Economic considerations. J Am Coll Cardiol 1987;10(suppl A):18-21A.
2. Weaver WD, Litwin PE, Martin JS et al. Effect of age on the use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991;18:657-662.
3. Smith Jr SC, Gilpin E, Ahnve S et al. Outlook after acute myocardial infarction in the very elderly compared with that in patients aged 65 to 75 years. J Am Coll Cardiol 1990;16:784-792.
4. Jajich CL, Ostfield AM, Freeman Jr DH. Smoking and coronary heart disease mortality in the elderly. JAMA 1984;252:2831-2834.
5. Siegel D, Kuller L, Lazarus NB et al. Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project. Am J Epidemiol 1987;126:385-399.
6. Kannel WB, Vokonas PS. Primary risk factors for coronary heart disease in the elderly: The Framingham Study. In: Wenger NK, Furberg CD, Pitt B, eds. Coronary Heart Disease in the Elderly. New York: Elsevier Science Publishing, 1986, pp 60-92.
7. Benfante R, Reed D, Frank J. Does cigarette smoking have an independent effect on coronary heart disease incidence in the elderly? Am J Public Health 1991;81:897-899.
8. LaCroix AZ, Lang J, Scherr P et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991;324:1619-1625.
9. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: Results from the CASS registry. N Engl J Med 1988;319:1365-1369.
10. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996;77:864-866.
11. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 1991;67:295-299.
12. Applegate WB, Rutan GH. Advances in management of hypertension in older persons. J Am Geriatr Soc 1992;40:1164-1174.
13. Amery A, Birkenhager W, Brixko P et al. Mortality and morbidity results from the European Working Party on Hypertension in Elderly Trial. Lancet 1985;1:1349-1354.
14. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP Hypertension). Lancet 1991;338:1281-1285.
15. MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: Principal results. Br Med J 1992;304:405-412.
16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
17. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
18. 1997 Joint National Committee. The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-2444.
19. Castelli WP, Wilson PWF, Levy D, Anderson K. Cardiovascular disease in the elderly. Am J Cardiol 1989;63:12-19H.
20. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham Study. Ann Intern Med 1991;115:687-693.
21. Benfante R, Reed D. Is elevated serum cholesterol level a factor for coronary heart disease in the elderly? JAMA 1990;263:393-396.
22. Barrett-Connor E, Suarez L, Khaw K-T et al. Ischemic heart disease risk factors after age 50. J Chronic Dis 1984;37:903-908.
23. Rubin SM, Sidney S, Black DM et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990;113: 916-920.
24. Zimetbaum P, Frishman WH, Ooi WL et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: The Bronx Aging Study. Arterioscler Thromb 1992;12:416-423.
25. Corti M-C, Guralnik JM, Salive ME et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995;274:539-544.
26. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1,793 men and women aged ≥62 years. Am J Cardiol 1994;73:702-703.
27. Lavie CJ, Milani RV. National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs. Am J Cardiol 1991;68:1087-1088.
28. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
29. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
30. Ryan TJ, Anderson JL, Antman EM et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1996;94:2341-2350.
31. Grundy SM, Balady GJ, Criqui MH et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: A statement for health care professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997;95:1683-1685.
32. Vokonas PS, Kannel WB. Epidemiology of coronary heart disease in the elderly. In: Tresch DD, Aronow WS, eds. Cardiovascular Disease in the Elderly Patient. New York: Marcel Dekker, 1994, pp 91-123.
33. Kannel WB, Cupples LA, Ramaswami R et al. Regional obesity and risk of cardiovascular disease. J Clin Epidemiol 1991;44:183-190.
34. Folsom AR, Kaye SA, Sellers TA et al. Body fat distribution and 5-year risk of death in older women. JAMA 1993;269:483-487.
35. Williams MA, Maresh CM, Aronow WS et al. The value of early outpatient cardiac exercise programmes for the elderly in comparison with other selected age groups. Eur Heart J 1984;5(suppl E):113-115.
36. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
37. Goldstein RE, Andrews M, Hall WJ, Moss AJ, for the Multicenter Myocardial Ischemia Research Group. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996;28:326-330.
38. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-396.
39. Chalmers TC, Malta RJ, Smith Jr H et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-1096.
40. The Sixty Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-994.
41. Smith P, Arnesen H, Holme I. Effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
42. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effects of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
43. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
44. Hansteen V. Beta blockade after myocardial infarction: The Norwegian Propranolol Study in high-risk patients. Circulation 1983;67(suppl I):I57-60.
45. Hjalmarson A, Herbiz J, Malek J et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981;2:823-827.
46. Gundersen T, Abrahamsen AM, Kjekshus J et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-1184.
47. Pedersen TR for the Norwegian Multicentre Study Group. Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction. N Engl J Med 1985;313:1055-1058.
48. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247: 1707-1714.
49. Park KC, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 1995;43:751-755.
50. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510.
51. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomised trials in post-infarction patients. Eur Heart J 1988;9:8-16.
52. Lichstein E, Hager WD, Gregory JJ et al. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol 1990;16:1327-1332.
53. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
54. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol 1997;80:207-209.
55. Soumerai SB, McLaughlin TJ, Spiegelman D et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121.
56. Aronow WS, Ahn C, Mercando AD et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 1994;74:267-270.
57. Kennedy HL, Brooks MM, Barker AH et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74:674-680.
58. Aronow WS, Ahn C, Mercando AD et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol 1994; 74:613-615.
59. Aronow WS, Ahn C, Mercando AD, Epstein S. Effect of propranolol on circadian variation of ventricular arrhythmias in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1995;75:514-516.
60. Aronow WS, Ahn C, Mercando AD, Epstein S. Effect of propranolol on circadian variation of myocardial ischemia in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1995;75:837-839.
61. Aronow WS, Ahn C, Mercando AD, Epstein S. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994;74:819-821.
62. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment subgroups of patients within a clinical trial: The case of non-Q-wave myocardial infarction and beta-blockers. Am J Cardiol 1990;60:220-222.
63. Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isorbide dinitrate after chronic use. Circulation 1977;56:205-212.
64. Parker JO, Farrell B, Lahey KA et al. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987;316: 1440-1444.
65. Olson HG, Aronow WS. Medical therapy of stable and unstable angina in the elderly. In: Aronow WS, Stemmer EA, Wilson SE, eds. Vascular Disease in the Elderly. Armonk: Futura, 1997, pp 267-292.
66. Cohn J, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
67. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-604.
68. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 1450-1456.
69. Philbin EF, Rocco Jr TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997;134:188-195.
70. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677.
71. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
72. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
73. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-1676.
74. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67:1295-1297.
75. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
76. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
77. Goldstein RE, Boccuzzi SJ, Cruess D et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
78. Danish Study Group on Verapamil in Myocardial Infarction. Trial II-DAVIT II: Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990;66:779-785.
79. Akiyama T, Pawitan Y, Campbell WB et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. J Am Geriatr Soc 1992;40:666-672.
80. Aronow WS, Mercando AD, Epstein S, Kronzon I. Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. Am J. Cardiol 1990;66:423-428.
81. Julian DJ, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142-1147.
82. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
83. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
84. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682.
85. Greene HL, for the CASCADE Investigators. The CASCADE study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 1993;72:70-74F.
86. Herre J, Sauve M, Malone P et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-449.
87. Friedman LM, Byington RP, Capone RJ et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986;7:1-8.
88. Norris RM, Barnaby PF, Brown MA et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984;2:883-886.
89. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
90. Tresch DD, Troup PJ, Thakur RK et al. Comparison of efficacy of automatic implantable cardioverter defibrillator in patients older and younger than 65 years of age. Am J Med 1991;90:717-724.
91. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
92. Grodstein F, Stampfer MJ. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
93. Psaty BM, Heckbert SR, Atkins D et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-1339.
94. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-461.
95. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-Up Study. Circulation 1987;75:1102-1109.
96. Gruchow HW, Anderson AJ, Barboriak JJ et al. Postmenopausal use of estrogen and occlusion of cornary arteries. Am Heart J 1988;115:954-963.
97. The Postmenopausal Estrogen/Progestin Interventions Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
98. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.
99. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-2551.
100. Rahimtoola SH, Fessler CL, Grunkemeier GL et al. Survival 15 to 20 years after coronary bypass surgery for angina. J Am Coll Cardiol 1993;21:151-157.
101. Weintraub WS, Clements SD, Ware J et al. Coronary artery surgery in octogenarians. Am J Cardiol 1991;68:1530-1534.
102. Buffet P, Danchin N, Juilliere Y et al. Percutaneous transluminal coronary angioplasty in patients more than 75 years old: Early and long-term results. Int J Cardiol 1992;37:33-39.
103. Reynen K, Kunkel B, Bachmann K et al. PTCA in elderly patients: Acute results and long-term follow-up. Eur Heart J 1993;14:1661-1668.
104. Thompson RC, Holmes Jr DR, Gersh BJ et al. Percutaneous transluminal coronary angioplasty in the elderly: Early and long-term results. J Am Coll Cardiol 1991;17:1245-1250.
105. Aronow WS. Appropriate use of coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty in older patients. Clin Geriatr 1996;4(2):15-22.